Double Good News For AstraZeneca’s Breast Cancer Drugs

Vandana Singh | April 29, 2024

AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study. The results showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine […]

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market

Vandana Singh | April 8, 2024

On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included […]